Chronic coronary syndrome with mild to moderate depression
Conditions
Interventions
Test Group:Kedaling tablets in combination with conventional medication
Control Group:Kedaling simulant combined with conventional treatment
Sponsors
Affiliated hangzhou first people's hospital, zhejiang university school of medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.18 years old = 8 and <= 24 on the Hamilton Depression Scale (HAMD-17) items at the screening period; 5.Clearly understand, voluntarily participate in the study, and sign an informed consent form;
Exclusion criteria
Exclusion criteria: 1.After a 1-week placebo introductory period, patients had a >= 25% reduction in HAMD-17 score compared with that at screening; 2.Patients with a previous history of suicide, or currently at serious risk of suicide, or a score of >= 3 on the HAMD-17 suicidality item; those with a history of epilepsy; depressive episodes of bipolar disorder, or depressive episodes secondary to other psychiatric or somatic disorders; 3.Severe anxiety, Hamilton Anxiety Scale (HAMA) score >21; 4.Acute myocardial events, unstable angina, severe heart failure; severe cardiac arrhythmias; severe or poorly controlled hypertension (systolic >= 180mmHg or diastolic >= 110mmHg); seated blood pressure systolic 3 times the upper limit of normal, and/or blood creatinine > 2 times the upper limit of normal); 7.Those who have taken selective 5-HT reuptake inhibitors (e.g. fluoxetine) within four weeks prior to enrolment; those who have taken monoamine oxidase inhibitors (e.g. phenelzine) within two weeks prior to enrolment; and those who are currently taking and need to take anti-anxiety medication or antidepressant medication for a long period of time. 8.Pregnant or breastfeeding women, women of childbearing age who are not using effective contraception or who are planning to conceive during the test, and those who have had a positive pregnancy test before the test. 9.Participants in other clinical trials within 30 days prior to screening; 10.Other reasons the researcher felt it would be inappropriate to participate in the trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| The Seattle Angina Scale;Routine blood tests, biochemistry, thyroid function, cortisol, C-reactive protein and interleukin; | — |
Countries
China
Contacts
Public ContactZhong Yigang; Xie Jianchang
Affiliated hangzhou first people's hospital, zhejiang university school of medicine
Outcome results
None listed